Avivagen Secures Large OxC-beta™ Livestock Order in Asia

Key Facts

• OTTAWA, Ontario--()--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce it has signed a significant new purchase agreement to supply its largest customer in Asia with a 6.3 tonne order of OxC-beta™ Livestock.

• “We’re extremely pleased to see the continued growth of this important customer in Asia, one of the most important regions worldwide for livestock feed production” > > Tweet this “We’re extremely pleased to see the continued growth of this important customer in Asia, one of the most important regions worldwide for livestock feed production,” says Kym Anthony, Chief Executive Officer, Avivagen Inc. “We believe that the fact that Avivagen’s customers continue to increase order size for OxC-beta™ amid a global pandemic is a clear sign of the positive impact that integration of our products can have on our customer’s bottom line.

• Statements set out in this news release relating to the future plans of Avivagen’s customers and the potential for additional and/or increased orders from such customers, anticipated growth in demand for Avivagen’s products, the anticipated date of fulfillment for the order described, the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded and the size of market opportunities are all forward-looking statements.
• For instance, the order described may not result in new orders for Avivagen’s products, the customer plans may change due to many reasons, demand for Avivagen’s products may not continue to grow and could decline, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications, including human applications, and may not be widely accepted as a replacement for antibiotics in livestock feeds, new market access may not occur in the timeline or manner expected by Avivagen, timing of fulfillment of the order may be delayed beyond current expectation for a number of reasons which would push fulfillment and recognition of revenues for this order into a future quarter or, in the worst case, cause the order to be terminated and the market opportunities may not be as large as Avivagen anticipates, in each case due to many factors, many of which are outside of Avivagen’s control.

Click To Read Full Article